Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 1.00 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.88 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | OGA | O60502 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23067576 | 0.93 | CRBN (1.00) | CRBNDDB1NPC1RAB9AKMT2A | |
| SCHEMBL21496461 | 0.86 | CRBN (0.82) | CRBNDDB1NPC1RAB9AKMT2A | |
| SCHEMBL21484121 | 0.82 | CRBN (1.00) | CRBNDDB1NPC1RAB9AKMT2A | |
| SCHEMBL21508838 | 0.79 | CRBN (0.65) | CRBNDDB1 | |
| SCHEMBL23067563 | 0.78 | CRBN (1.00) | CRBNDDB1NPC1RAB9AKMT2A | |
| SCHEMBL31068518 | 0.77 | CRBN (0.70) | CRBNDDB1NPC1RAB9AKMT2A | |
| SCHEMBL3895677 | 0.77 | RAB9A (0.72) | CRBNDDB1NPC1RAB9AKMT2A | |
| SCHEMBL21508841 | 0.77 | CRBN (0.66) | CRBNDDB1 | |
| SCHEMBL27088173 | 0.77 | CRBN (0.66) | CRBNDDB1NPC1RAB9AKMT2A | |
| SCHEMBL1639895 | 0.77 | HDAC1 (0.63) | CRBNDDB1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3556760-A1 | SPIRO COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2019-10-23 | — | — | EP | claimed |
| CN-119751456-A | Spiro compounds | C4医药公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-112312904-B | Spiro compounds | C4医药公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20230416251-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | US | disclosed |
| US-11584748-B2 | Spirocyclic compounds | C4 THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11584748-B2 | Spirocyclic compounds | C4 THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210032245-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | US | disclosed |
| US-20210032245-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | US | disclosed |
| EP-3556760-A1 | SPIRO COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2019-10-23 | — | — | EP | disclosed |
| EP-3556760-A1 | SPIRO COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2019-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416251-A1 | SPIROCYCLIC COMPOUNDS | CRBN, RBX1, XIAP | CRBN 1/4885DDB1 143/4885NPC1 2125/4885 |
| US-20210032245-A1 | SPIROCYCLIC COMPOUNDS | CRBN, RBX1, XIAP | CRBN 1/4885DDB1 143/4885NPC1 2125/4885 |
| US-11584748-B2 | Spirocyclic compounds | CRBN, RBX1, XIAP | CRBN 1/4885DDB1 143/4885NPC1 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.